ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Cell Signaling
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1579470
This article is part of the Research TopicPhytochemical Interventions to CancerView all 7 articles
A Systematic Review and Meta-analysis of the Effects of of Green Tea Extracts and Polyphenols in Female Hormone-Dependent Cancers for Benefit-Risk Evaluation
Provisionally accepted
- 1Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, China
- 2The 903rd Hospital of The Chinese People’s Liberation Army, Hangzhou, Jiangsu Province, China
- 3Zhejiang Hospital, Hangzhou, Zhejiang Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Female hormone-dependent cancers rely on estrogen for growth and include breast, uterine and ovarian cancers. Although preclinical studies indicate that green tea extracts and polyphenols derived from green tea exhibit anti-tumor effects without mimicking estrogen like phytoestrogens, clinical evidence remains scarce. To explore the potential of green tea products in inhibiting these cancers, we conducted a meta-analysis of preclinical data. We evaluated the effects of green tea extract (GTE), green tea polyphenol-enriched product (GTP), and epigallocatechin gallate (EGCG) on tumor growth indices in mouse and rat models of breast, ovarian, and uterine cancers. A comprehensive search of PubMed, Web of Science, and Google Scholar (1998-2024) identified 20 studies for inclusion. Pooled analysis showed significant reductions in tumor volume (Hedge's g = -2.332, 95% CI = -3.067 to -1.596, p = 0.000) and tumor weight (Hedge's g = -2.105, 95% CI = -2.746 to -1.463, p = 0.000). Subgroup analysis revealed that GTE and EGCG reduced breast and ovarian tumors, while EGCG had no significant impact on uterine cancer. Significant heterogeneity was observed across studies. No consistent adverse effects were reported in the included studies, though liver function parameters were not assessed. These findings highlight the necessity for targeted clinical trials to assess the distinct benefits of each tea-based product for various cancer types.
Keywords: green tea extract, Green tea polyphenols, breast cancer, ovarian cancer, Uterine Cancer, Meta-analysis Normal (Web)
Received: 12 Mar 2025; Accepted: 21 Aug 2025.
Copyright: © 2025 He, Zhang, He and Lei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zheng Lei, Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.